



**Key Indices Update** 

Indices	Close	Change (%)
Nifty	24039.35	<b>ل</b> 68.0
Sensex	79212.53	0.74ע
Midcap	53570.20	ב2.55
Smallcap	16547.20	2.45ש

#### Trend Strength Indicator

Nifty 50 Stocks above	NSE Advance /
200 EMA	Decline
26	455 <mark>/2428</mark>

#### **Key Data**

Data	Current	Previous
Dow Jones	39,968.5	40,142.5
U.S. Dollar Index	99.65	99.61
Brent Crude (USD/BBL)	66.92	66.80
US 10Y Bond Yield (%)	4.25	4.32
India 10Y Bond Yield (%)	6.37	6.35

### Sectoral Data

Contor	Close	Change (%)
Sector	Close	Change (%)
BANKNIFTY	54558.05	ו.17
NIFTYAUTO	21957.05	1.844
NIFTYENERG	33891.3	2.41ك
NIFTYFINSR	27660.05	ו.71
NIFTYFMCG	56428.45	עו8.0
NIFTYIT	35489	0.527
NIFTYMEDIA	1542.8	3.54ك
NIFTYMETAL	8536.5	2.48ك
NIFTYPHARM	21449.75	2.39ك
NIFTYREALT	857.6	3.002

APRIL 28, **2025** 

### **Fundamental**

Refer Page 02

#### Stock for Investment

Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
CAMS	Financial Services	3,938	4,390	11.5%

\*CMP as on Apr. 25, 2025

#### **Top News**

- + Mahindra and Mahindra Limited has acquired 43.96% of the equity share capital of SML Isuzu Limited ("SML") from Sumitomo Corporation ("Sumitomo Corp.") for a cash consideration of ₹650 per equity share. The total transaction value aggregates to ₹413.55 crore, subject to receipt of applicable statutory and regulatory approvals.
- + Zydus Lifesciences is slated to buy 85.6% of Amplitude Surgical SA for Euro 256.8 million, with plans to delist the firm following a squeeze-out procedure.

### **Technical**

Refer Page 03-04

- + Nifty began the first day of the new derivatives series on a weak note, primarily weighed down by escalating geopolitical tensions between India and Pakistan.
- + After an initial uptick, the Nifty witnessed a sharp decline in the first half; however, a rebound in select heavyweight stocks helped pare some losses later in the session.
- + Across sectors, most traded in the red, with realty, pharma, and energy emerging as the top losers.
- + On the benchmark front, sustaining above the 23,800 level is crucial for Nifty to retain its positive bias; failure to do so could lead to further profit-taking.
- + Given the prevailing environment, we maintain a cautious stance and recommend a hedged approach for existing positions.
- + Stock of the day MARICO





### **Fundamental**

### Top News

01

Mahindra and Mahindra Limited has acquired 43.96% of the equity share capital of SML Isuzu Limited ("SML") from Sumitomo Corporation ("Sumitomo Corp.") for a cash consideration of ₹650 per equity share. The total transaction value aggregates to ₹413.55 crore, subject to receipt of applicable statutory and regulatory approvals.

02

**Zydus Lifesciences** is slated to **buy 85.6% of Amplitude Surgical SA for Euro 256.8 million**, with plans to delist the firm following a squeeze-out procedure.

03

**RailTel Corporation** has **secured** a domestic **ERP work order worth INR 90.08 crore** from The Institute Of Road Transport.

04

Alembic Pharmaceuticals invested roughly Rs. 205 Cr in establishing a new formulation production facility in Pithampur.

05

**IDFC First** Bank **to raise Rs. 7,500 Cr from Warburg Pincus and ADIA**, boosting its capital adequacy.

### Stock

## Computer Age Management Services Ltd

Stock Symbol	CAMS
Sector	Financial Services
*CMP (₹)	3,938
^Target Price (₹)	4,390
Upside	11.5%
*CMP as on Apr. 25, 2025	
^Time horizon - upto 11 Months	

- + CAMS is India's leading technology-driven financial infrastructure and services provider, primarily serving the mutual fund (MF) industry as the largest Registrar and Transfer Agent (RTA), with a market share of 68% based on MF AUM
- + Company operates in **a business with high entry barriers**, as the Mutual Fund RTA industry requires **advanced technology and a scalable ecosystem** to manage **vast transaction volumes** and data processing
- + CAMS is **expanding beyond its core Mutual Fund RTA business** into high-growth segments, **leveraging its technological expertise**, **regulatory knowledge, and client relationships** to drive long-term growth and reduce revenue concentration.
- + Company is a leading play on Indian AUM growth, as its core business as a Mutual Fund RTA generates a significant portion of revenue from a percentage fee on AUM of its client Mutual Funds (MFs). Approximately 74% of CAMS's revenue is derived from AUM-based fees, benefiting from industry inflows and market appreciation.
- → We estimate CAMS's revenue, EBITDA, and PAT to grow at a CAGR of 21.5%, 23.2%, and 24.1% over FY24-27E, respectively. Accordingly, we set a target price of ₹4,390 with Buy rating.





### **Technical**

### Critical to hold 23,800. Prefer hedged positions.

NIFTY	S1
24039.35 🔰 207.35 (0.86%)	2380

S1	<b>S2</b>	RI	R2
23800	23500	24200	24400



- + Nifty began the first day of the new derivatives series on a weak note, primarily weighed down by escalating geopolitical tensions between India and Pakistan.
- + Across sectors, most traded in the red, with realty, pharma, and energy emerging as the top losers.
- On the benchmark front, sustaining above the 23,800 level is crucial for Nifty to retain its positive bias; failure to do so could lead to further profit-taking.
- Given the prevailing environment, we maintain a cautious stance and recommend a hedged approach for existing positions.

BANKNIFTY	S1	\$2	RI	R2
54664.05 🔰 537.35 (0.97%)	53900	53600	55100	55600



- The banking index began the May series on a weak note, registering a loss of around one percent.
- Most banking majors declined wherein Axisbank suffered the most after its earning announcement, while Icicibank and Indusindbk ended on flat note.
- + Now, a close above the recent high around 26100 would lead to the resumption of the upward rally.
- On the downside, support for the index is placed in the 54100-53800 zone. The intermediate resistance lies at 55400-55600.





### **Technical**

Stock of the day	Recom.	<b>CMP</b> (₹)	Range*	SL	Target
MARICO	BUY	710.40	708-711	685	755



- + Marico has been **trading in a steady uptrend, forming base on base pattern** above its key long term averages.
- The stock has formed an elevated base above the neckline of its breakout zone, setting ground for the next leg of up move.
- The steady rising structure with supportive volumes, signals an inherent strength in price.
- + Traders can consider long in the mentioned range.

Stocks	۵
Momentum	Midca

Name	Price	Price %
RBA	81.99	5.457
JUBLINGREA	689.00	1.327
LXCHEM	184.47	0.457
CYIENT	1175.00	5.46¥
MOTILALOFS	691.95	8.47צ

Name	Price	Price %
VOLTAS	1226.60	וב 3.87
SYNGENE	629.00	3.73ك
-	-	-
-	-	-
-	-	-

Gainers 7	Name	Price	Price %
	SBILIFE	1691.00	5.157
	MPHASIS	2524.00	2.267
Top 5 F&O	PERSISTENT	5259.00	1.997
	COFORGE	7375.00	1.717
	MFSL	1263.80	1.297

Name	Price	Price %	70
SHRIRAMFIN	640.00	8.13 <i>\</i>	Гор 5
ANGELONE	2322.90	لا7.03	F&O
SBICARD	864.85	6.662	
ACC	1935.00	6.35ك	Losers
IDEA	7.46	5.932	K

ırts	Name	Price	Price %
	INDUSINDBK	820.00	0.037
Charts	MFSL	1263.80	1.297
Bullish	SBILIFE	1691.00	5.157
Bu	TECHM	1460.00	1.027
	ULTRACEMCO	12190.00	0.257

Name	Price	Price %	
ANGELONE	2322.90	لا7.03	Bearish
CYIENT	1176.00	ב-5.37	
PFC	412.00	בוו.5	Charts
RBLBANK	187.40	ב5.50	rts
SHRIRAMFIN	640.00	8.13 <b>u</b>	





# **Research Team**

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Vinay Kalani	vinay.kalani1@religare.com
Rajan Gupta	rajan.gupta1@religare.com





### **Disclaimer**

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <a href="https://www.religareonline.com/disclaimer">https://www.religareonline.com/disclaimer</a>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation—Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under  $F(\alpha)$  to F(j) below, are given separately]:

S. No.	Statement		Answer	
		Yes	No	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]	-	No	
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No	
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No	
	I/we have received any compensation from the subject company in the past twelve months?		No	
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No	
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No	
	I/we have served as an officer, director or employee of the subject company?		No	
	I/we have been engaged in market making activity for the subject company?		No	

Nature of Interest if answer to F(a) above is Yes:	Name(s) with Signature(s) of RA(s)

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results







